Biota Pharmaceuticals Inc (NASDAQ:BOTA)

Delayed Data
As of Mar 04
 0.00 / 0.00%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV). In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV). Biota Pharmaceuticals was founded on November 8, 2012 and is headquartered in Alpharetta, GA.

Contact Information

Biota Pharmaceuticals, Inc.
2500 Northwinds Parkway
Alpharetta Georgia 30009
P:(678) 221-3343
Investor Relations:



Other institutional30.17%
Mutual fund holders10.85%
Individual stakeholders1.91%

Top Executives

Russell H. PlumbExecutive Chairman & Chief Financial Officer
Joseph M. PattiPresident, Chief Executive Officer & Director
Anna Novotney-BarryVice President-Clinical Development
John H. VernachioVice President-Preclinical Development
Simon P. TuckerVice President-Research

To view my watchlist

Not a member yet?

Sign up now for a free account